monoclonal antibodies

Even though oral antiviral drugs and monoclonal antibodies help people recover from COVID-19, a new report found that nursing homes didn’t use the medications much during the pandemic.  

Trial results for AstraZeneca’s experimental antibody, a potential replacement for Evusheld, could be out by September. The company is hoping for emergency use authorization by the end of 2023.

New data on Lilly’s experimental drug donanemab may influence CMS’s restrictive stance on coverage of this and other amyloid-busting Alzheimer’s treatments, a company executive says.

For two years, monoclonal antibodies were approved, revoked and sometimes reauthorized or scarce, but pushing through these challenges “unequivocally saved lives and prevented hospitalizations,”...

Health and Human Services Secretary Xavier Becerra came under fire Wednesday during a Senate Finance Committee meeting regarding the Centers for Medicare & Medicaid Services’ restrictive national...

The Alzheimer’s Association is lobbying lawmakers to convince the Biden administration to reconsider a decision not to provide full coverage for new Alzheimer’s drugs which the organization believes...

Two emerging omicron subvariants will likely evade monoclonal antibody treatment. Antiviral drugs, however, should retain their efficacy, investigators have found.

Evusheld, a preventive COVID-19 antibody for high-risk patients, may lose efficacy in the face of newly emerging variants, the FDA has informed clinicians.

Some U.S. clinicians continued to rely on two monoclonal antibody treatments for COVID after they were deauthorized by the FDA, researchers report.

A new order of the injectable COVID antibody bebtelovimab should meet current demand levels through August, according to the Department of Health and Human Services.